CA2656379A1 - Differential cytokine expression in human cancer - Google Patents

Differential cytokine expression in human cancer Download PDF

Info

Publication number
CA2656379A1
CA2656379A1 CA002656379A CA2656379A CA2656379A1 CA 2656379 A1 CA2656379 A1 CA 2656379A1 CA 002656379 A CA002656379 A CA 002656379A CA 2656379 A CA2656379 A CA 2656379A CA 2656379 A1 CA2656379 A1 CA 2656379A1
Authority
CA
Canada
Prior art keywords
tumour
cytokine
apoptotic
cells
chemotherapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002656379A
Other languages
English (en)
French (fr)
Inventor
Giorgio Stassi
Christian Gieffers
Oliver Hill
Meinolf Thiemann
Matilde Todaro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apogenix AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2656379A1 publication Critical patent/CA2656379A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CA002656379A 2006-06-21 2007-06-21 Differential cytokine expression in human cancer Abandoned CA2656379A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06012754.5 2006-06-21
EP06012754 2006-06-21
PCT/EP2007/005480 WO2007147600A2 (en) 2006-06-21 2007-06-21 Differential il-4 and/or il-10 cytokine expression in human cancer

Publications (1)

Publication Number Publication Date
CA2656379A1 true CA2656379A1 (en) 2007-12-27

Family

ID=38359749

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002656379A Abandoned CA2656379A1 (en) 2006-06-21 2007-06-21 Differential cytokine expression in human cancer

Country Status (12)

Country Link
US (1) US20090324616A1 (https=)
EP (1) EP2041576B1 (https=)
JP (1) JP2010514409A (https=)
CN (1) CN101529253A (https=)
AT (1) ATE520032T1 (https=)
AU (1) AU2007263265A1 (https=)
BR (1) BRPI0713484A2 (https=)
CA (1) CA2656379A1 (https=)
DK (1) DK2041576T3 (https=)
ES (1) ES2371287T3 (https=)
RU (1) RU2009101783A (https=)
WO (1) WO2007147600A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2646626A1 (en) * 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treatment of cancer
US20100086515A1 (en) * 2006-07-06 2010-04-08 Apogenix Gmbh Human il-4 muteins in cancer therapy
EP3409686B1 (en) * 2012-07-18 2022-04-13 Apogenix AG Composition comprising a mixture of cd95-fc isoforms
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
AU2015335607B2 (en) * 2014-10-24 2020-04-23 Calidi Biotherapeutics (Nevada), Inc. Combination immunotherapy approach for treatment of cancer
CN108135996B (zh) 2015-08-11 2022-06-21 卡利迪生物治疗有限公司 用以癌症治疗的天花疫苗
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
EA201892260A1 (ru) 2016-04-07 2019-03-29 Дзе Джонс Хопкинс Юниверсити Композиции и способы для лечения панкреатита и боли с применением агонистов рецептора смерти
EP4053557A1 (en) * 2016-11-24 2022-09-07 Huvet Bio, Inc. Il-29 as a marker for a pancreatic disease
CN111051349A (zh) * 2017-09-06 2020-04-21 弗雷德哈钦森癌症研究中心 Strep-tag特异性嵌合受体及其用途
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) * 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung
US6534051B1 (en) * 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
WO1995007301A1 (en) 1993-09-07 1995-03-16 Smithkline Beecham Corporation Recombinant il4 antibodies useful in treatment of il4 mediated disorders
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
AU686816B2 (en) * 1994-07-05 1998-02-12 Steeno Research Group A/S Immunomodulators
HUT76369A (en) * 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US20030124125A1 (en) * 1996-04-05 2003-07-03 South Alabama Medical Science Foundation Oncofetal antigen specific T-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10
US6028176A (en) * 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
CA2309598A1 (en) * 1997-11-10 1999-05-20 Mochida Pharmaceutical Co., Ltd. Preventives and remedies for diffuse lung disease
JPH11312463A (ja) * 1998-04-28 1999-11-09 Hitachi Ltd 配線基板およびそれを用いたガス放電型表示装置
WO2001074388A1 (en) * 2000-03-31 2001-10-11 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
AU2001273413A1 (en) * 2000-07-12 2002-01-21 Immunex Corporation Method for treating cancer using an interleukin- 4 antagonist
US20040023338A1 (en) * 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
CA2464695A1 (en) * 2001-10-26 2003-05-01 Centocor, Inc. Il-13 mutein proteins, antibodies, compositions, methods and uses
EP1444989A1 (en) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
EP1824886B1 (en) * 2004-11-17 2010-12-22 Amgen Inc. Fully human monoclonal antibodies to il-13
US20070122855A1 (en) * 2005-11-28 2007-05-31 Targetgen Inc. Methods for diagnosing hepatocellular carcinoma
CA2646626A1 (en) * 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treatment of cancer
US20100086515A1 (en) * 2006-07-06 2010-04-08 Apogenix Gmbh Human il-4 muteins in cancer therapy

Also Published As

Publication number Publication date
WO2007147600A2 (en) 2007-12-27
EP2041576A2 (en) 2009-04-01
BRPI0713484A2 (pt) 2012-11-06
EP2041576B1 (en) 2011-08-10
RU2009101783A (ru) 2010-07-27
ATE520032T1 (de) 2011-08-15
DK2041576T3 (da) 2011-12-05
JP2010514409A (ja) 2010-05-06
CN101529253A (zh) 2009-09-09
US20090324616A1 (en) 2009-12-31
AU2007263265A1 (en) 2007-12-27
ES2371287T3 (es) 2011-12-29
WO2007147600A3 (en) 2008-04-10

Similar Documents

Publication Publication Date Title
EP2041576B1 (en) Differential cytokine expression in human cancer
Koornstra et al. Expression of TRAIL (TNF‐related apoptosis‐inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas
JP6812364B2 (ja) 癌診断用抗ｇｉｔｒ抗体
DeFazio-Eli et al. Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action
Meinhold-Heerlein et al. Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer
US20150118244A1 (en) Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
Barresi et al. Sstr2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microvessel density?
Schinagl et al. Oxidized macrophage migration inhibitory factor is a potential new tissue marker and drug target in cancer
JP2014505239A (ja) 癌の治療または検出のための抗ｃｘｃｌ１３および抗ｃｘｃｒ５抗体の使用
CA3076997C (en) Anti-ckap4 monoclonal antibody
Ruiz-Ruiz et al. p53-mediated up-regulation of CD95 is not involved in genotoxic drug-induced apoptosis of human breast tumor cells
Xie et al. Formyl peptide receptor 2 expression predicts poor prognosis and promotes invasion and metastasis in epithelial ovarian cancer
Costes et al. Expression of the interleukin 6 receptor in primary renal cell carcinoma.
Ekshyyan et al. Rapamycin targets Interleukin 6 (IL-6) expression and suppresses endothelial cell invasion stimulated by tumor cells
KR20210107730A (ko) 골수 형성이상 증후군의 치료 또는 예방에서의 il-1 베타 항체의 용도
Urra et al. Differential expression profile of CXCR3 splicing variants is associated with thyroid neoplasia. Potential role in papillary thyroid carcinoma oncogenesis?
Liu et al. Desensitization of T lymphocyte function by CXCR3 ligands in human hepatocellular carcinoma
US8969020B2 (en) Peptide sequence that promotes tumor invasion
US20120015352A1 (en) Method of determining sensitivity of human or non-human animal cells to an iap antagonist
Wu Circulating tumor markers of the new millennium: target therapy, early detection, and prognosis
Zhu et al. Expression of chemokines CCL5 and CCL11 by smooth muscle tumor cells of the uterus and its possible role in the recruitment of mast cells
Hill et al. Identification of a distinctive p‐glycoprotein‐mediated resistance phenotype in human ovarian carcinoma cells after their in vitro exposure to fractionated x‐irradiation
TW528801B (en) Monoclonal antibodies for the detection of decoy receptor 3, hybridomas producing said antibodies and uses thereof
Seol et al. Aggressive vestibular schwannomas showing postoperative rapid growth–their association with decreased p27 expression
JP2011522872A (ja) エフリンａ型受容体７タンパク質

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130621